| Ticker Details |
Cel-Sci Corporation
CEL-SCI Corp is a biotechnology company. It is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.
|
| IPO Date: |
December 1, 1984 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$20.58M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.20 | 5.09%
|
| Avg Daily Range (30 D): |
$0.17 | 7.24%
|
| Avg Daily Range (90 D): |
$0.20 | 5.48%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.85M |
| Avg Daily Volume (30 D): |
.6M |
| Avg Daily Volume (90 D): |
.24M |
| Trade Size |
| Avg Trade Size (Sh.): |
461 |
| Avg Trade Size (Sh.) (30 D): |
233 |
| Avg Trade Size (Sh.) (90 D): |
209 |
| Institutional Trades |
| Total Institutional Trades: |
351 |
| Avg Institutional Trade: |
$1.44M |
| Avg Institutional Trade (30 D): |
$1.32M |
| Avg Institutional Trade (90 D): |
$1.32M |
| Avg Institutional Trade Volume: |
M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.59M |
| Avg Closing Trade (30 D): |
$1.32M |
| Avg Closing Trade (90 D): |
$1.32M |
| Avg Closing Volume: |
5.66K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
$-2.64
|
$-.67
|
$-.68
|
|
Revenue
|
$-.51M
|
$-.12M
|
$-.09M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$49.99M
|
$5.47M
|
$5.47M
|
|
Operating Income / Loss
|
$-22.22M
|
$-5.33M
|
$-5.37M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$9.03M
|
$M
|
$M
|
|
PE Ratio
|
|
|
|
| Splits |
|
May 20, 2025
|
1:30
|
|
Jun 15, 2017
|
1:25
|
|
Sep 25, 2013
|
1:10
|
|
|
|